Understanding how T cells affect graft-versus-host disease and leukemia treatment

ID3 regulation of tissue-infiltrating T cells mediating graft-versus-host disease and leukemia rejection

NIH-funded research Hackensack University Medical Center · NIH-11081734

This study is looking at how certain immune cells called T cells affect the success of stem cell transplants for blood cancers like leukemia, with the goal of finding better ways to reduce complications like graft-versus-host disease while still helping to fight the cancer.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionHackensack University Medical Center NIH-funded
Lab location1 site (Hackensack, United States)
Project IDNIH-11081734 on NIH RePORTER

What this research studies

This research investigates the role of specific T cells in graft-versus-host disease (GVHD) and their impact on the success of stem cell transplants for treating blood cancers like leukemia. The study focuses on how these T cells persist in the body and how they can be better managed to reduce GVHD while still effectively fighting cancer. By exploring the mechanisms that allow these T cells to survive and function, the research aims to develop improved strategies for managing GVHD and preventing cancer relapse after transplantation.

Who could benefit from this research

Good fit: Ideal candidates for this research are patients undergoing allogeneic hematopoietic stem cell transplantation for hematological cancers such as leukemia, lymphoma, or myeloma.

Not a fit: Patients who are not undergoing stem cell transplantation or those with solid tumors may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to more effective treatments for patients undergoing stem cell transplants, reducing the risk of GVHD and improving cancer outcomes.

How similar studies have performed: Previous research has shown promise in managing GVHD through various immunosuppressive strategies, indicating that this approach could lead to significant advancements in treatment.

Where this research is happening

Hackensack, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions anti-cancer immunotherapyanticancer immunotherapy
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.